Cytek Aurora Full Spectrum Flow Cytometer

项目摘要 Sanford Burnham Prebys医学发现研究所（SBP）拥有约40个研究分子和细胞生物学的实验室。 各种生物过程的基础，包括癌症;发育生物学;免疫肿瘤学; 感染、炎症、衰老及相关疾病。许多医疗保健的最新进展依赖于新的 在单细胞水平上深入了解组织异质性。流式细胞术是高通量的金标准 单细胞分析，然而，常规的流动受限于可以一致运行的分析物的数量。 光谱流式细胞仪最近实现了深度免疫分析所需的参数深度， 出版物显示40+色竞争飞行时间质谱仪（CyTOF）参数深度， 更高的吞吐量。 SBP请求支持Cytek Aurora光谱流式细胞仪，配有5个激光器（UV/V/B/YG/R），64 荧光和3个散射通道，以及自动微量取样站（AMS）， 参数单细胞蛋白质组学分析，用于组织中细胞异质性的深度剖析。我们还请 支持Cytek Aurora的BioBUBBLE I类阴性生物防护外壳，以保护 研究人员在研究潜在的传染性物质极光使荧光的数量增加了一倍多 可以在SBP测量的参数，并利用现有的FACS协议和专业知识。这是一个桥梁 SBP核心的高通量低倍常规流式细胞仪和高倍低倍流式细胞仪之间的技术 基于通量基因组学的单细胞Seq技术。 这个应用程序是由SBP和附近的加州大学旧金山分校的12个主要用户组成的联盟支持的 圣地亚哥（UCSD）和圣地亚哥生物医学研究所（SDBRI）展示了对 地区NIH资助的研究人员，共占75%的极光的可用使用时间（AUT），需要 Aurora推进了他们对T细胞耗竭、抗肿瘤免疫、衰老、多系统 儿童炎性疾病（MIS-C）、肠粘膜免疫、黑色素瘤、胰腺癌、乳腺癌 小儿髓母细胞瘤、移植物抗宿主病和冠状病毒的免疫逃避策略。的 Aurora将提供对与健康和疾病相关的组织特征的前所未有的洞察， 新的机械研究和发现。

PROJECT SUMMARY Sanford Burnham Prebys Medical Discovery Institute (SBP) has ~40 labs studying the molecular and cellular underpinnings of diverse biological processes including cancer; developmental biology; immuno-oncology; infection, inflammation; aging and related diseases. Many recent advances in health care depend upon new insights into tissue heterogeneity at the single cell level. Flow cytometry is the gold standard for high throughput single cell analysis, however conventional flow is limited by the number of analytes that can be run in unison. Spectral flow cytometers recently achieved the parameter depth required for deep immune profiling with publications showing 40+ color rivaling time-of-flight mass cytometry (CyTOF) parameter depth with ~50-fold higher throughput. SBP requests support for a Cytek Aurora Spectral Flow Cytometer with 5 lasers (UV/V/B/YG/R), 64 fluorescence and 3 scattering channels, and Automatic Micro-sampling Station (AMS) to enable high- parameter single-cell proteomic analysis for deep profiling of cell heterogeneity in tissues. We also request support for a BioBUBBLE Class I Negative Biocontainment Enclosure for Cytek Aurora to protect researchers running potentially infectious material. The Aurora more than doubles the number of fluorescent parameters that can be measured at SBP and leverages existing FACS protocols and expertise. It is a bridging technology between high-throughput low-plex conventional flow cytometers in SBP’s Core and high-plex low- throughput genomics-based single-cell Seq technologies. This application is supported by a coalition of 12 Major Users from SBP and nearby University of California San Diego (UCSD) and San Diego Biomedical Research Institute (SDBRI) demonstrating the broad impact for the region. NIH-funded researchers, together accounting for 75% of the Aurora’s available use time (AUT), need the Aurora to advance their understanding of T cell exhaustion, anti-tumor immunity, aging, multi-system inflammatory disease in children (MIS-C), gut mucosal immunity, melanoma, pancreatic cancer, breast cancer, pediatric medulloblastoma, graft versus host disease, and the immune evasion tactics of Coronavirus. The Aurora will provide unprecedented insight into tissue signatures that correlate with health and disease leading to new mechanistic inquiries and discoveries.